A phase I trial of fixed-dose-rate (FDR) gemcitabine and irinotecan combination in patients with advanced pancreatic and biliary cancer.

被引：0
|
作者：
Sun, W [1 ]
Theobald, ME [1 ]
Hershock, D [1 ]
Haller, DG [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4112
引用
收藏
页码：341S / 341S
页数：1
相关论文
共 50 条
  • [1] A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer
    Sun, Weijing
    Hewitt, Maureen R.
    Theobald, Marry R.
    Hershock, Diane
    Haller, Daniel G.
    [J]. CANCER, 2007, 110 (12) : 2768 - 2774
  • [2] Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma
    Mane, Joan M.
    Sancho, Aintzane
    Munoz, Alberto
    Rubio, Itziar
    Fernandez, Ricardo
    Carrera, Sergio
    Fuente, Natalia
    Ballesteros, David
    Casas, Raquel
    Marrodan, Ines
    Mielgo, Xabier
    Lopez-Vivanco, Guillermo
    [J]. TUMORI, 2010, 96 (03) : 405 - 410
  • [3] Phase I of fixed-dose-rate gemcitabine in combination with bortezomib in patients with advanced solid tumors
    Luu, T. H.
    Chow, W. A.
    Lim, D.
    Koczywas, M.
    Frankle, P.
    Cristea, M.
    Somlo, G.
    Morgan, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
    Santini, D.
    Vincenzi, B.
    Masi, G.
    Catalano, V
    Virzi, V.
    Vasile, E.
    Fontana, A.
    Intagliata, S.
    Catalano, G.
    Falcone, A.
    Tonini, G.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 59 - 60
  • [5] PHASE II CAPECITABINE AND GEMCITABINE FIXED DOSE RATE (FDR) IN PATIENTS WITH ADVANCED PANCREATIC CANCER
    Santini, D.
    Vincenzi, B.
    Masi, G.
    Catalano, V
    Virzi, V.
    Vasile, E.
    Fontana, A.
    Intagliata, S.
    Catalano, G.
    Falcone, A.
    Tonini, G.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 104 - 104
  • [6] Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
    Santini, D.
    Vincenzi, B.
    Masi, G.
    Catalano, V.
    Virzi, V.
    Fontana, A.
    Vasile, E.
    Intagliata, S.
    Catalano, G.
    Falcone, A.
    Tonini, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
    Tonini, G.
    Vincenzi, B.
    Vasile, E.
    Catalano, V.
    Virzi, V.
    Fontana, A.
    Intagliata, S.
    Catalano, G.
    Falcone, A.
    Santini, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201)
    Poplin, E.
    Levy, D. E.
    Berlin, J.
    Rothenberg, M. L.
    O'Dwyer, P. J.
    Cella, D.
    Mitchell, E.
    Alberts, S.
    Benson, A., III
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 933S - 933S
  • [9] Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer
    Milella, Michele
    Gelibter, Alain J.
    Pino, Maria Simona
    Bossone, Giandominik
    Marolla, Paolo
    Sperduti, Isabella
    Cognetti, Francesco
    [J]. ONCOLOGIST, 2010, 15 (02): : E1 - E4
  • [10] Phase I trial of gefitinib with concurrent radiotherapy and fixed dose-rate gemcitabine infusion, in locally advanced pancreatic cancer.
    Maurel, J.
    Martin-Richard, M.
    Conill, C.
    Sanchez, M.
    Petriz, L.
    Ginés, A.
    Gallego, R.
    Cajal, R.
    Navarro, S.
    Fernandez-Cruz, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 204S - 204S
12345